Equities Analysts Offer Predictions for Eli Lilly and Company’s Q3 2017 Earnings (LLY)

Eli Lilly and Company (NYSE:LLY) – Investment analysts at Jefferies Group issued their Q3 2017 earnings per share estimates for shares of Eli Lilly and in a report released on Wednesday. Jefferies Group analyst J. Holford expects that the company will post earnings per share of $1.01 for the quarter. Jefferies Group currently has a “Buy” rating and a $89.00 price objective on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2018 earnings at $4.84 EPS and FY2019 earnings at $5.10 EPS.

A number of other research firms have also recently commented on LLY. Morgan Stanley set a $86.00 target price on Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. BMO Capital Markets raised their target price on Eli Lilly and from $71.00 to $73.00 and gave the company an “underperform” rating in a research report on Tuesday, October 10th. Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and raised their target price for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research report on Friday, October 13th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $88.97.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/10/20/equities-analysts-offer-predictions-for-eli-lilly-and-companys-q3-2017-earnings-lly.html.

Eli Lilly and (NYSE LLY) opened at 86.36 on Thursday. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $89.09. The stock has a market capitalization of $91.11 billion, a P/E ratio of 37.37 and a beta of 0.34. The stock has a 50 day moving average price of $84.21 and a 200 day moving average price of $82.27.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the previous year, the business earned $0.86 earnings per share. The business’s revenue was up 7.8% on a year-over-year basis.

Several hedge funds and other institutional investors have recently made changes to their positions in LLY. Waldron LP increased its holdings in shares of Eli Lilly and by 46.7% during the 1st quarter. Waldron LP now owns 4,948 shares of the company’s stock worth $415,000 after buying an additional 1,574 shares during the last quarter. Strategic Advisors LLC acquired a new stake in shares of Eli Lilly and during the 1st quarter worth approximately $396,000. Wellington Shields Capital Management LLC increased its holdings in shares of Eli Lilly and by 4.0% during the 1st quarter. Wellington Shields Capital Management LLC now owns 18,332 shares of the company’s stock worth $1,542,000 after buying an additional 700 shares during the last quarter. Baltimore Capital Management Inc. acquired a new stake in shares of Eli Lilly and during the 1st quarter worth approximately $289,000. Finally, Texas Yale Capital Corp. increased its holdings in shares of Eli Lilly and by 25.8% during the 1st quarter. Texas Yale Capital Corp. now owns 14,615 shares of the company’s stock worth $1,229,000 after buying an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 75.53% of the company’s stock.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 990,000 shares of company stock worth $82,949,650 over the last three months. Corporate insiders own 0.20% of the company’s stock.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discove

Eli Lilly and Company (NYSE:LLY) – Investment analysts at Jefferies Group issued their Q3 2017 earnings per share estimates for shares of Eli Lilly and in a report released on Wednesday. Jefferies Group analyst J. Holford expects that the company will post earnings per share of $1.01 for the quarter. Jefferies Group currently has a “Buy” rating and a $89.00 price objective on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2018 earnings at $4.84 EPS and FY2019 earnings at $5.10 EPS.

A number of other research firms have also recently commented on LLY. Morgan Stanley set a $86.00 target price on Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. BMO Capital Markets raised their target price on Eli Lilly and from $71.00 to $73.00 and gave the company an “underperform” rating in a research report on Tuesday, October 10th. Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and raised their target price for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research report on Friday, October 13th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $88.97.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/10/20/equities-analysts-offer-predictions-for-eli-lilly-and-companys-q3-2017-earnings-lly.html.

Eli Lilly and (NYSE LLY) opened at 86.36 on Thursday. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $89.09. The stock has a market capitalization of $91.11 billion, a P/E ratio of 37.37 and a beta of 0.34. The stock has a 50 day moving average price of $84.21 and a 200 day moving average price of $82.27.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the previous year, the business earned $0.86 earnings per share. The business’s revenue was up 7.8% on a year-over-year basis.

Several hedge funds and other institutional investors have recently made changes to their positions in LLY. Waldron LP increased its holdings in shares of Eli Lilly and by 46.7% during the 1st quarter. Waldron LP now owns 4,948 shares of the company’s stock worth $415,000 after buying an additional 1,574 shares during the last quarter. Strategic Advisors LLC acquired a new stake in shares of Eli Lilly and during the 1st quarter worth approximately $396,000. Wellington Shields Capital Management LLC increased its holdings in shares of Eli Lilly and by 4.0% during the 1st quarter. Wellington Shields Capital Management LLC now owns 18,332 shares of the company’s stock worth $1,542,000 after buying an additional 700 shares during the last quarter. Baltimore Capital Management Inc. acquired a new stake in shares of Eli Lilly and during the 1st quarter worth approximately $289,000. Finally, Texas Yale Capital Corp. increased its holdings in shares of Eli Lilly and by 25.8% during the 1st quarter. Texas Yale Capital Corp. now owns 14,615 shares of the company’s stock worth $1,229,000 after buying an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 75.53% of the company’s stock.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 990,000 shares of company stock worth $82,949,650 over the last three months. Corporate insiders own 0.20% of the company’s stock.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply